437649-96-2

Upstream product

• 437657-41-5 N'-[(tert-butoxycarbonyl)oxy]-4-(2-mercapto-1,3-thiazol-4-yl)benzenecarboximidamide 
• 437649-94-0 allyl imino[4-(2-mercapto-1,3-thiazol-4-yl)phenyl]methylcarbamate 
• 437649-93-9 4-(2-mercapto-1,3-thiazol-4-yl)benzenecarboximidamide 
• 437657-42-6 N'-hydroxy-4-(2-mercapto-1,3-thiazol-4-yl)benzenecarboximidamide 
• 52560-96-0 4-(2-mercapto-1,3-thiazol-4-yl)benzonitrile 
• 437649-95-1 allyl (4R,5S,6S)-3-[(4-{4-[{[(allyloxy)carbonyl]amino}(imino)methyl]phenyl}-1,3-thiazol-2-yl)thio]-4-methyl-7-oxo-6-{(1R)-1-[(trimethylsilyl)oxy]ethyl}-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate 

Relevant academic research and scientific papers

New anti-MRSA and anti-VRE carbapenems: Synthesis and structure-activity relationships of 1β-metyl-2-(thiazol-2-ylthio)carbapenems

Discovery of novel antimicrobial agents effective against infections caused by drug-resistant pathogens is an important objective. In order to find a new parenteral carbapenem antibiotic, which has potent antibacterial activity especially against methicillin-resistant staphylococci, vancomycin-resistant enterococci and penicillin-resistant Streptococcus pneumoniae, a series of 1β-methylcarbapenems with thiazol-2-ylthio groups at the C-2 position have been synthesized. Structure-activity relationships were investigated which led to SM-197436 (27), SM-232721 (44) and SM-232724 (41), being selected for further evaluation.